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Abstract
Mutations in the SOD1 and TARDBP genes have been commonly identified in Amyotrophic Lateral Sclerosis (ALS). Recently,
mutations in the Fused in sarcoma gene (FUS) were identified in familial (FALS) ALS cases and sporadic (SALS) patients.
Similarly to TDP-43 (coded by TARDBP gene), FUS is an RNA binding protein. Using the zebrafish (Danio rerio), we examined
the consequences of expressing human wild-type (WT) FUS and three ALS–related mutations, as well as their interactions
with TARDBP and SOD1. Knockdown of zebrafish Fus yielded a motor phenotype that could be rescued upon co-expression
of wild-type human FUS. In contrast, the two most frequent ALS–related FUS mutations, R521H and R521C, unlike S57D,
failed to rescue the knockdown phenotype, indicating loss of function. The R521H mutation caused a toxic gain of function
when expressed alone, similar to the phenotype observed upon knockdown of zebrafish Fus. This phenotype was not
aggravated by co-expression of both mutant human TARDBP (G348C) and FUS (R521H) or by knockdown of both zebrafish
Tardbp and Fus, consistent with a common pathogenic mechanism. We also observed that WT FUS rescued the Tardbp
knockdown phenotype, but not vice versa, suggesting that TARDBP acts upstream of FUS in this pathway. In addition we
observed that WT SOD1 failed to rescue the phenotype observed upon overexpression of mutant TARDBP or FUS or upon
knockdown of Tardbp or Fus; similarly, WT TARDBP or FUS also failed to rescue the phenotype induced by mutant SOD1
(G93A). Finally, overexpression of mutant SOD1 exacerbated the motor phenotype caused by overexpression of mutant FUS.
Together our results indicate that TARDBP and FUS act in a pathogenic pathway that is independent of SOD1.
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Introduction
ALS is the most common motor neuron disorder and is
characterized by loss of upper and lower motor neurons. It is the
third most common neurological disorder with an incidence of 1–2
people in 100,000, a prevalence of 4–6 per 100,000 and with a
lifetime risk of 1 in 1,000 [1,2]. ALS has a devastating course with
disease onset generally first detected at 50–60 years of age followed
by rapid muscle weakness, atrophy and eventual paralysis resulting
in death due to respiratory failure within 1–5 years. Approximately
10% of ALS patients have a familial history for this disease (FALS),
whereas the majority (90%) of cases appears to be of a sporadic
nature (SALS) [3,4]. So far, three major genes have been
implicated in ALS: SOD1, TARDBP and FUS. However, it is not
known whether these three genes interact in a common pathway
or represent distinct ALS etiologies.
Cu/Zn superoxide dismutase (SOD1) mutations were the first to
be identified predominantly in FALS patients in 1993, with more
than 130 mutations currently identified in approximately 20% of
FALS patients [2,4–6]. A toxic gain of function of mutant SOD1
causes pronounced motor deficits in vivo correlated to motor
neuron degeneration in a number of animal models [2,7,8].
Recently, mutations in TAR DNA binding protein (TARDBP) [9–
12] and Fused in sarcoma (FUS) [13,14] genes were found in both
FALS and SALS patients, opening novel possibilities of studying
the predominant, sporadic form of this disease [11,15]. In 2008,
two concurrent reports, including ours, identified a dozen missense
mutations in the TARDBP gene [9–11]. So far, 38 TARDBP
mutations have been identified predominantly clustered in the C-
terminus, glycine-rich region of the TDP-43 protein encoded by
the TARDBP gene in approximately1% of SALS and 3% of FALS
[11,16]. Two concurrent publications in 2009 identified FUS
mutations that occur in about 5% of FALS and less than 1% of
SALS [11,16] with 35 mutations so far identified in ALS cases.
Similarly to TDP-43 (encoded by TARDBP), FUS is an RNA
binding protein mainly localized in the nucleus [11]. Further
comparable to the TARDBP mutations identified in ALS cases,
most of the FUS mutations cluster in the C-terminus of the FUS
protein, including the most common mutations, R521C present in
22 FALS and 4 SALS and R521H present in 9 FALS and 4 SALS
[11,13,14,17–28]. Interestingly, both proteins have been found to
be major components of ubiquitinated inclusion bodies in autopsy
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related neurodegenerative disorders, such as frontotemporal lobar
degeneration (FTLD), Alzheimer’s and Parkinson’s diseases
[11,16]. In rare cases, either TARDBP or FUS mutations have
also been identified in FTLD cases with or without motor neuron
involvement [29–32].
In line with this genetic evidence, pathological reports have
shown that TDP-43 and FUS antibodies co-label protein
aggregates consisting of inclusion bodies observed in both SALS
and FALS cases [33], distinguishing these aggregates from the
SOD1 positive found in FALS patients [34]. Two recent studies in
cell lines have shown that TDP-43 and FUS interact [35] with a
report showing that both proteins are able to influence HDAC6
mRNA production [36]. Strong overexpression of both TARDBP
and FUS (either WT or carrying ALS mutations) were shown to
exacerbate a degenerative phenotype in the Drosophila eye as
compared to either gene alone [37]. Further, recent studies have
also demonstrated that depletion of TARDBP using RNAi in cell
lines or tardbp in Drosophila leads to specific decrease in FUS mRNA
levels [38,39]. Overall, this evidence suggests that these proteins
are involved in similar pathogenic mechanisms leading to motor
neuron degeneration. However, the relevance of TARDBP and
FUS mutations to these pathogenic mechanisms is not well
understood, since none of the known functions of TDP-43 and
FUS, such as binding to RNA, DNA and heterogeneous nuclear
ribonucleoproteins (hnRNPs), have been shown to be perturbed by
ALS-related mutations [36,40,41].
Recent insight in neurodegenerative diseases has revealed that
several genes mutated in these disorders could participate in
common molecular mechanisms, raising the possibility of a
multigenic interaction at the root of the pathogenesis of
neurodegeneration. One such example is the well-established
genetic and functional interaction between PTEN-induced
putative (mitochondrial) kinase 1 (PINK1) and the E3 ubiquitin
ligase parkin (PRKN) [42,43], two genes mutated in Parkinson’s
disease [44,45]. Another recent example is the identification of
interactions between TDP-43 and ataxin-2 in vivo, with ataxin-2
containing polyglutamine expansions being a potent modifier of
TDP-43 toxicity [46]. This interaction was also found to have
pathogenic implications since SCA1 triplet repeats are significantly
increased in ALS patients as compared to controls [46].
In order to establish whether genetic interactions also exist in
ALS pathogenesis we carried out a multigenic analysis of FUS,
TARDBP and SOD1 in zebrafish. Zebrafish are proving to be a
valuable vertebrate model to further our understanding of these
multigenic interactions [47]. A number of recent studies in
zebrafish with relevance to motor neuron diseases [8,48–52]
suggest that this vertebrate organism is ideally suited as a model to
rapidly and efficiently replicate certain aspects of these disorders
[53]. This allows us to better understand genetic (and eventually
the cellular and molecular) mechanisms of motor neuron
degeneration during a much shorter time span (in this case inside
a few days). Further, these models allow us to define the crucial
steps in disease development and to find ways to interfere with the
development of early hallmarks of the disease, rather than to
exactly replicate the (likely later) symptoms.
We have previously demonstrated that mutations of TARDBP
cause a pronounced motor phenotype characterized by aberrant
motor neuron morphology and motor behavior in zebrafish
through both toxic gain and loss of function [50], with the toxic
gain of function results being recently confirmed by another group
[48]. Up to now, this represents the only vertebrate model of
mutant TARDBP where a motor neuron disorder has been
observed when compared to similar expression of WT TARDBP.
Here we report that FUS mutations identified in ALS patients
present a similar motor phenotype. Our results reveal a common
genetic pathway for FUS and TARDBP in vivo, with FUS possibly
acting downstream of TARDBP. These results also establish that
SOD1 acts independently of FUS/TARDBP in causing a motor
phenotype in these genetic models of ALS. The establishment of
these new genetic models for ALS provides new tools to study the
molecular mechanisms of neurodegeneration.
Results
FUS mutations characterized in this study
Three ALS-related mutations identified in our patient cohort at
the University of Montre ´al Health Centre (CHUM; individuals
from Quebec and France) were selected for this study. The R521C
is the most common FUS mutation identified so far in 22 FALS
and 4 SALS in a number of cohorts. The R521H mutation is also
a very common mutation accounting for 9 FALS and 4 SALS
[11,13,14,17–28]. Both of these mutations have been shown to
mislocalize from the nucleus to the cytosol in a number of cell line
experiments [14,54,55]. The S57D mutation was identified in one
SALS patient from our cohort and is one of the only variants
identified in ALS cases to be located in the N-terminus region of
the FUS protein [19].
Loss of function of Fus leads to a motor phenotype that
can be rescued by WT FUS but not ALS–related
mutations
We first confirmed by in situ hybridization that Fus mRNA
was indeed expressed as early as 24 hours post-fertilization (hpf)
in zebrafish embryos (Figure 1A) mainly in the hindbrain, eye
and intersomitic segments as well as the spinal cord (Figure 1B).
The antisense morpholino oligonucleotide (AMO) for Fus KD
was designed to specifically bind near the ATG of zebrafish Fus
but nowhere else in the zebrafish genome. As a control, a
mismatch AMO was also designed that does not bind anywhere
in the zebrafish genome. Western blot analysis using a FUS
antibody demonstrated knockdown (KD) of Fus expression by
approximately 60% solely in fish injected with an AMO
Author Summary
Mutations in the SOD1, TARDBP, and FUS genes have been
commonly identified in Amyotrophic Lateral Sclerosis
(ALS). However, possible interactions between these
ALS–causative genetic mutations have not been examined.
Here we expressed each of three human FUS mutations
(R521H, R521C, and S57D) in zebrafish embryos, with or
without knocking down the zebrafish homolog Fus, and
observed a motor phenotype consisting of significant
behavioral (touch-evoked escape response) and cellular
(shortened axonal projections from motor neurons)
deficits due to loss of function for the R521H and R521C
mutations and/or toxic gain of function solely for the
R521H mutation. Wild-type FUS could rescue the Tardbp
knockdown phenotype, but not vice versa, suggesting that
TARDBP is upstream of FUS in this pathway responsible for
motor neuron disorder. Furthermore, neither TARDBP nor
FUS were able to modify and/or rescue the motor
phenotype caused by mutant SOD1, and likewise SOD1
failed to rescue the phenotype of zebrafish expressing
mutant TARDBP or FUS. Our results indicate that TARDBP
acts upstream of FUS in a pathogenic pathway that is
distinct from that of SOD1.
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(Figure 1C).
Fus KD by AMO caused motor deficits consisting of a
significantly abnormal motor behaviour measured as a deficient
touch-evoked escape response (TEER) (Figure 2Ai) as well as
reduced outgrowth of hyperbranched axons from motor neurons
or unbranched axonal length (UAL) (Figure 2Bi) that we
subsequently refer to as the motor phenotype. The TEER was
deficient in 57% of fish injected but was negligible in zebrafish
non-injected (2%), sham injected (3%) or injected with mismatch
AMO (7%). Only 26% of larvae injected with Fus AMO displayed
a normal touch-evoked escape response (Figure 2Ci) as compared
to 95% in non-injected, 87% in sham-injected and 82% in larvae
injected with the mismatch AMO. Similarly, the length of the
motor axons to the point of the first branch (UAL) was significantly
reduced in larvae injected with Fus AMO when compared to non-
injected zebrafish from 99 to 76 mm (Figure 2B, 2Ci). These results
are summarized in Table 1 row 1–4.
To determine if the human FUS and the zebrafish Fus genes are
functionally similar, we co-injected human WT FUS mRNA
alongside Fus AMO. The motor phenotype was rescued in these
sets of injections when compared to injections of Fus AMO alone
with significant increases of the percentages of zebrafish displaying
a normal TEER from 26 to 70% as well as augmentation of the
UAL of motor neurons from 76 to 91 mm (Figure 2A, 2B, 2Ci
versus 2A, 2B, 2Cii and Table 1 rows 4–5).
Next, we examined whether mutations in the FUS gene can
cause loss of function and result in a motor phenotype similar to
what we previously demonstrated for TARDBP mutations [50].
Contrary to WT FUS mRNA, co-injection of R521H FUS mRNA
and Fus AMO (Figure 2Ciii) did not rescue the motor phenotype
(21% of zebrafish with normal TEER and the UAL from motor
neurons measured at 74 mm). Co-injection of the R521C FUS
mRNA partially rescued this phenotype, from 26% with AMO
(see above) to 48% of zebrafish displaying a normal TEER and
UAL of 80 mm (Figure 2Civ and Figure S1A, S1Biii) since it was
also found to be significantly different from the rescue of Fus KD
by WT FUS mRNA injection with 70% of fish with normal TEER
and UAL of 91 mm (Figure 2A, 2B, 2Cii). However, co-injection of
S57D FUS mRNA completely rescued the phenotype induced by
Fus AMO (Figure 2Cv and Figure S1A, S1Biv) to a similar degree
as the co-injection WT FUS mRNA injection (Figure 2A, 2B, 2Cii)
with 64% versus 70% of zebrafish displaying a normal TEER and
UAL at 92 versus 91 mm. These results are summarized in Table 1
rows 4–8.
Toxic gain of function of mutant FUS
Furthermore, we determined whether expression of WT and
ALS-related mutant FUS mRNAs by themselves caused a motor
deficit in zebrafish. Upon overexpression of R521H FUS mRNA
in zebrafish embryos we observed a motor phenotype with only
43% of zebrafish larvae displaying a normal TEER (Figure 2Aiv,
2Cvi) as compared to 77% upon WT FUS injection (Figure 2Aiii,
2Cix). Similarly, the UAL of motor neurons overexpressing
R521H FUS (Figure 2Biv, 2Cvi) was reduced to 78 mma s
compared to 94 mm upon WT FUS injection (Figure 2Biii, 2Cix).
Surprisingly, expression at similar levels of the R521C FUS mRNA
(Figure S1A, S1Bi and Figure 2Cvii) and the S57D FUS mutations
(Figure S1A, S1Bii and Figure 2Cviii) did not elicit a motor
phenotype with similar percentages of embryos displaying a
normal TEER (R521C: 63% and S57D: 72% versus WT: 77%;
Figure 2Cvii,viii and Figure S1Ai,ii) as described above for WT
FUS mRNA (Figure 2Aiii, 2Cix). Similarly, the length of the UAL
of motor neurons was not significantly altered when compared to
WT FUS (Figure 2Cix) (R521C: 93 mm and S57D:9 8mm versus
WT: 91 mm; Figure 2Cvii,viii and Figure S1Bi,ii). These and
subsequent sets of injections presented below did not significantly
affect percentages of developmentally deficient (,10%) and of
dead embryos (,10%) within our conditions (data not shown).
The differences observed upon mRNA injections were not due to
different levels of protein expression, since Western blot analysis
revealed no changes in expression between the WT protein and
the three ALS-related FUS mutants described here (Figure 1D).
The results from this section are summarized in Table 1 rows 9–
12.These data indicate that the ALS-related R521H mutation of
FUS can cause motor neuron deficits leading to a toxic gain of
function.
Figure 1. Fus mRNA expression in early development of zebrafish and Fus levels are reduced upon KD with a specific AMO. A) In situ
hybridization with antisense (upper panels) and sense (lower panel) oligo probes specific to Fus mRNA revealed a predominant expression in the CNS,
in particular in the hindbrain, spinal cord, as well as intersomitic segments as shown in B) in 24 hpf zebrafish embryos. C) Western blot analysis of
zebrafish embryos injected with an AMO that specifically binds and inhibits Fus mRNA translation, showing reduced levels of Fus expression as
compared to non-injected zebrafish embryos and zebrafish embryos injected with an AMO, where 5 nucleotides are mismatched (mismatch). D) WT
human FUS mRNA or one of three ALS-related FUS mutations, each tagged with myc, were overexpressed in zebrafish and larval extracts were
collected. Immunoblotting with myc antibody reveals similar expression in all these extracts.
doi:10.1371/journal.pgen.1002214.g001
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function (R521H) or solely loss of function (R521C) can render
FUS mutations pathogenic. A lack of phenotype for the S57D FUS
could indicate that this variant may be a rare polymorphism not
causing disease. In accordance with this functional characteriza-
tion performed in our zebrafish model, the R521H and R521C
FUS mutations have been identified in a large number of FALS
and SALS cases with both these mutations segregating with disease
in large families, whereas the S57D variant was identified only in
one SALS case [11,13,14,17–28].
Genetic interactions between FUS and TARDBP
We hypothesized that FUS and TARDBP operate through a
common genetic pathway. To examine this possibility, we tested
whether FUS or TARDBP could rescue the loss of function
phenotype caused by knockdown of either of these genes in
zebrafish. WT FUS mRNA was able to rescue the motor
phenotype (49% of zebrafish with normal TEER and UAL of
83 mm) (Figure 3Aii and Figure 4A, 4Biii) caused by Tardbp KD
alone (27% of zebrafish with normal TEER and UAL of 71 mm)
(Figure 3Ai), similarly to the rescue observed with WT TARDBP
(59% of zebrafish with normal TEER and UAL of 86 mm)
(Figure 3Aiii and Figure 4A, 4Bii). In contrast, co-injection of WT
TARDBP mRNA with Fus AMO alone (28% of zebrafish with
normal TEER and UAL of 77 mm) (Figure 3Biii and Figure 4A,
4Biv) was unable to rescue the phenotype obtained by KD of Fus
alone (26% of zebrafish with normal TEER and UAL of 76 mm)
(Figure 2A, 2Bi and Figure 3Bi). As mentioned previously, co-
injection of WT FUS mRNA with Fus AMO (Figure 2A, 2Bii and
Figure 3Bii) was able to properly rescue the motor phenotype
caused by Fus KD alone (Figure 2A, 2Bi and Figure 3Bi). The
results from this section are summarized in Table 1 row 4, 13–14
and 16–17. These results demonstrate that a genetic interaction
between FUS and TARDBP exists, with FUS overexpression being
able to rescue the Tardbp KD phenotype as a downstream effector.
TAF15 has a high structural and functional homology to FUS,
since both TAF15 and FUS belong to the class of TET family of
multifunctional DNA/RNA-binding proteins [56]. TAF15 has
Figure 2. ALS-related FUS mutations cause a motor phenotype through both gain and loss of function. A) KD of Fus (i) causes a major
deficit in the TEER, which can be rescued by WT FUS mRNA (ii). A similar motor phenotype is also observed upon overexpression of mutant R521H
FUS mRNA (iv), but not WT FUS mRNA alone (iii). B) Immunocytochemical analysis of axonal projections from spinal cord motor neurons revealed a
marked reduction of primary axonal length (arrowheads represent the unbranched axonal length; UAL) upon KD of zebrafish Fus, which could be
rescued by co-expression of WT FUS mRNA (ii). A similar axonal phenotype is also observed upon overexpression of mutant FUS mRNA (iv), but not
present in zebrafish expressing WT FUS mRNA (iii) alone. C) Both the percentage of fish with normal TEER (upward bars, averages of % of normal
zebrafish (ZF) embryos 6 standard errors of mean, SEM) and the length of primary motor axons (downward bars, averages of UAL in mm 6 SEM) were
unaffected or significantly reduced (* for p,0.05 from WT FUS mRNA injections; ** for p,0.05 from WT FUS mRNA injections and Fus AMO; all values
given in Table 1) when compared to fish injected with Fus AMO alone (i), Fus AMO and WT FUS (ii), Fus AMO and R521H FUS (iii), Fus AMO and R521C
FUS (iv) and Fus AMO and S57D FUS (v), or with R521H FUS (vi), R521C FUS (vii), S57D FUS (viii) or with WT FUS mRNA alone (ix). Arrowheads represent
length to the first axonal branching (UAL). Scale bar: 40 mm.
doi:10.1371/journal.pgen.1002214.g002
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few variants identified solely in FALS cases, but not in controls
[57]. We thus determined the motor phenotype upon Tardbp
KD with or without overexpression of TAF15 mRNA.
Overexpression of TAF15 mRNA did not cause an overt motor
phenotype with 65% displaying a normal TEER. Co-injecting
TAF15 mRNA with Tardbp AMO (33% of zebrafish with normal
TEER) failed to rescue the motor phenotype caused by Tardbp
KD alone (27% of zebrafish with normal TEER). (Figure S2).
These results further ascertain that the rescue of the phenotype
induced by Tardbp KD by overexpressing WT FUS mRNA is
specific to this gene and could be independent of the known
functions of FUS and its homologue TAF15, such as DNA and/
or RNA binding.
Table 1. Summary of the motor phenotype quantification in the ALS matrix.
Conditions % Phenotype % Normal UAL N n Figure
Non Injected 2 94.8 99.2 753 32 n/a
Mis Fus AMO 6.9 81.6 N.D. 87 3 n/a
Sham Injected 3.5 87.7 N.D. 114 4 n/a
Fus AMO 56.9 25.9 75.9 437 12 2Ci + 3Bi + 5Aiv
Fus AMO + WT FUS 16.2 70.3 91.1 185 6 2Cii+3Bii
Fus AMO + R521H FUS 61.9 21.1 74.1 147 4 2Ciii
Fus AMO + R521C FUS 34.3 47.9 80.2 169 5 2Civ
Fus AMO + S57del FUS 19.1 63.8 92 94 3 2Cv
R521H FUS 38.4 42.6 78.3 284 9 2Cvi + 3Di + 5Ai
R521C FUS 18.5 63.1 93.1 157 5 2Cvii
S57del FUS 12.2 72.5 97.8 92 3 2Cviii
WT FUS 9.8 77.4 93.9 204 6 2Cix
Tardbp AMO 58.1 26.6 70.9 327 8 3Ai + 5Av
Tardbp AMO + WT TARDBP 19.9 58.9 86.1 151 4 3Aiii
WT TARDBP 18 61 89.1 128 3 n/a
Tardbp AMO + WT FUS 32.6 49.4 83.4 172 5 3Aii
Fus AMO + WT TARDBP 58.1 27.7 77.1 148 5 3Biii
Fus + Tardbp AMOs 59 20.9 69.3 139 4 5Avi
G348CTARDBP 54.3 23.5 75.6 221 6 3Ci + 5Aii
G348CTARDBP + R521H FUS 47.1 25 75.3 104 3 5Aiii
R521H FUS + WT TARDBP 30.8 40.7 78.1 91 3 3Diii
R521H FUS + WT FUS 35.6 41.4 78.9 87 3 3Dii
G348C TARDBP + WT TARDBP 44 21.1 70.5 109 3 3Ciii
G348C TARDBP + WT FUS 48.9 22.9 73 96 3 3Cii
WT SOD1 8 68.2 N.D. 88 3 n/a
Tardbp AMO + WT SOD1 58.5 25.5 71.8 94 3 3Aiv
Fus AMO + WT SOD1 57.1 29.5 76.2 112 3 3Biv
G348CTARDBP + WT SOD1 53.8 21.5 75.3 93 3 3Civ
R521H FUS + WT SOD1 38.8 41.2 75.9 85 3 3Div
Sod1 AMO 12.3 67.9 N.D. 81 3 n/a
Sod1 + Tardbp AMOs 55.8 25.2 71.9 104 3 3Av
Sod1 + Fus AMOs 58.7 25 75.4 92 2 3Bv
Sod1 AMO + G348CTARDBP 58.4 22.5 75.6 89 3 3Cv
Sod1 AMO + R521H FUS 39.2 40.2 78.2 102 3 3Dv
G93A SOD1 33.1 44.4 81.4 223 5 5Bi
G93A SOD1 + WT FUS 34.6 42.1 76.4 107 3 5Bii
G93ASOD1 + WT TARDBP 33 44 80.2 91 3 5Biii
G93A SOD1 + R521H FUS 58.8 17 67.9 153 5 5Biv
G93ASOD1 + G348C TARDBP 57.2 19.2 68.4 187 5 5Bv
Summary of the motor phenotype quantifications (TEER; % and UAL; mm) for all the conditions described in this study. After each experiment (n), embryos (N) were
separated into four groups and the percentages were calculated for dead and developmentally deficient (2–20%, data not shown) as well as normally developed fish
with delayed (phenotype) or normal swimming following the TEER. Also the length (mm) of the axonal projections (UAL) from motor neurons was assessed for each
group. The last row indicates the Figure where these data are presented.
doi:10.1371/journal.pgen.1002214.t001
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caused by the toxic gain of function of FUS could be rescued by
overexpression of WT TARDBP and vice-versa (a dozen combina-
tions; Figure 3A–3D, i–iii), expecting that a toxic gain of function
may be irreversible. We and others have previously demonstrated
that overexpression of mutant TARDBP causes a similar motor
phenotype to the one described above, most pronounced upon
injection of the G348C mutation [48,50]. Overexpression of this
mutant caused deficits in TEER in 54% of zebrafish with only
23% displaying a normal TEER and reduced UAL of motor axons
(76 mm) (Figure 3Ci). Our results show that co-expression of
mutant TARDBP with either WT FUS (23% of zebrafish with
normal TEER and UAL of 73 mm) (Figure 3Cii) or WT TARDBP
(21% of zebrafish with normal TEER and UAL of 70 mm)
(Figure 3Ciii) failed to rescue the toxic gain of function phenotype
caused by mutant TARDBP alone (23% of zebrafish with normal
TEER and UAL of 76 mm) (Figure 3Ci). Similarly, we were unable
to rescue the motor phenotype caused by expression of the R521H
mutant FUS (43% of zebrafish with normal TEER and UAL of
78 mm) (Figure 2A, 2Biv and Figure 3Di) with either WT TARDBP
(41% of zebrafish with normal TEER and UAL of 78 mm)
(Figure 3Diii) or WT FUS (41% of zebrafish with normal TEER
and UAL of 79 mm) (Figure 3Dii). The data from this section are
summarized in Table 1 rows 9, 19–24.Thus, overexpression of
WT FUS or TARDBP did not rescue the motor phenotype
generated by ALS-related mutations in these two genes, consistent
with their toxic gain of function.
If TARDBP and FUS interact, then overexpression of both
mutant TARDBP and FUS mRNAs or simultaneous KD of both
genes should yield a similar motor phenotype, whereas an
exaggerated, additive phenotype could be expected if these genes
act in independent pathways (see below for SOD1). As predicted
for interacting genes, a similar, non-exacerbated motor phenotype
was observed upon injection of the R521H mutant FUS (43% of
zebrafish with normal TEER and UAL of 78 mm) (Figure 2A, 2Biv
and Figure 5Ai), G348C mutant TARDBP (23% of zebrafish with
normal TEER and UAL of 76 mm), (Figure 5Aii and Figure 6A,
6Biii) or both mutant TARDBP and FUS (25% of zebrafish with
normal TEER and UAL of 75 mm) (Figure 5Aiii and Figure 6A,
6Biv). We also determined that co-injection of Fus and Tardbp
AMOs (21% of zebrafish with normal TEER and UAL of 69 mm)
(Figure 5Avi and Figure 6A, 6Bii) did not exacerbate the KD
motor phenotype observed upon injection of either Fus AMO
(26% of zebrafish with normal TEER and UAL of 76 mm)
(Figure 5Aiv and Figure 2A, 2Bi) or Tardbp AMO (27% of
zebrafish with normal TEER and UAL of 71 mm) (Figure 5Av and
Figure 6A, 6Bi). These data are summarized in Table 1 rows 4, 9,
13 and 18–20. Since injections of two AMOs might harbor robust
effects that would not allow the proper visualization of a possible
exacerbation of the motor phenotype, we also injected suboptimal
doses (see Materials and Methods) of both Fus and Tardbp AMOs
and compared the motor phenotype with the one induced by
single injection of Fus and/or Tardbp AMOs. The motor
phenotype was not significantly altered when subdoses (half) of
both Fus and Tardbp AMOs (61% of zebrafish with normal TEER
versus 21% at the higher dose) was compared to single AMO
injection of either Tardbp (63% of zebrafish with normal TEER
versus 26% at the higher dose) and/or Fus (69% of zebrafish with
normal TEER versus 27% at the higher dose) (Figure S3). Similar
results were thus obtained when using either full or subdoses of
both Fus and Tardbp AMOs.
Lack of genetic interactions between FUS/TARDBP and
SOD1
Having provided evidence for an in vivo genetic interaction
between TARDBP and FUS we sought to determine whether SOD1
interacts with these genes by performing further gain and loss of
function genetic manipulations using a specific Sod1 AMO, as well
as WT or mutant (G93A) SOD1 mRNAs. We then sought to
determine whether SOD1 acted downstream, upstream or
independently of TARDBP or FUS, comprising nineteen conditions
(Figure 3A–3D iv–v grey background and Figure 4A, 4Bv and
Figure 4vi). We first tested if SOD1 acts downstream of TARDBP
and FUS by examining whether WT SOD1 could rescue the motor
phenotypes generated by loss or toxic gain of function of TARDBP
or FUS. Overexpression of WT SOD1 did not yield a motor
phenotype on its own (motor phenotype consisting of 68% of
zebrafish with normal TEER) and failed to rescue the motor
phenotype induced by KD of Tardbp (25% of zebrafish with
normal TEER and UAL of 72 mm) (Figure 3Aiv and Figure 4A,
4Bvi), KD of Fus, (29% of zebrafish with normal TEER and UAL
of 76 mm) (Figure 3Biv and Figure 4A, 4Bv) as well as
overexpression of the G348C mutant TARDBP (21% of zebrafish
with normal TEER and UAL of 75 mm) (Figure 3Civ), or the
R521H mutant FUS (41% of zebrafish with normal TEER and
UAL of 76 mm) (Figure 3Div). Next, we tested whether KD of Sod1
could alleviate the motor phenotype caused by mutant TARDBP
or FUS. Injection of an AMO to specifically KD Sod1 did not cause
a motor phenotype on its own (consisting of 68% of zebrafish with
normal TEER), consistent with the lack of phenotype observed in
SOD1 knockout mice [58]. In contrast, co-injection of AMOs to
Sod1 and Tardbp (25% of zebrafish with normal TEER and UAL of
72 mm) (Figure 3Av) or to Sod1 and Fus (25% of zebrafish with
normal TEER and UAL of 75 mm) (Figure 3Bv) yielded a similar
motor phenotype to that observed upon KD of Tardbp (motor
phenotype consisting of 27% of zebrafish with normal TEER and
UAL of 71 mm) (Figure 3Ai and Figure 6A, 6Bi) or Fus (26% of
zebrafish with normal TEER and UAL of 76 mm) (Figure 2A, 2Bi
and Figure 3Bi) alone. Co-injection of Sod1 AMO with mutant
TARDBP (22% of zebrafish with normal TEER and UAL of
75 mm) (Figure 3Cv) or mutant FUS (40% of zebrafish with normal
TEER and UAL of 78 mm) (Figure 3Dv) also failed to modify the
motor phenotype obtained by injecting mutant TARDBP alone
(21% of zebrafish with normal TEER and UAL of 75 mm)
(Figure 3Ci and Figure 6A, 6Biii) and mutant FUS alone (motor
phenotype consisting of 43% of zebrafish with normal TEER and
UAL of 78 mm) (Figure 2A, 2Biv, Figure 3Di). From these
combined results we can infer that SOD1 is not acting downstream
of TARDBP or FUS. These results are summarized in Table 1 rows
4, 9, 13, 19 and 25–34.
Alternatively, to determine if SOD1 acts upstream we tested for
rescue of the mutant SOD1-induced motor phenotype by
Figure 3. FUS and TARDBP genetically interact independently of SOD1. Percentage of embryos able to swim away having a normal TEER
(upward bars, averages of % of normal ZF embryos 6 SEM) and the length of primary motor axons (downward bars, averages of UAL in mm 6 SEM)
were measured upon injection of either A) Tardbp AMO (downward scale represents gene knock-down), B) Fus AMO, C) G348C mutant TARDBP mRNA
(upward scale represents mRNA overexpression) or D) R521H mutant FUS mRNA alone (none; i) or along with injection of either WT FUS mRNA (ii), WT
TARDBP mRNA (iii), Sod1 AMO (iv, grey background) or SOD1 mRNA (v, grey background). Red bars represent failure to rescue the motor phenotype
from the KD (A,Bi) or mutant overexpression (C,Di), whereas green bars show rescue (* p,0.05; all values given in Table 1).
doi:10.1371/journal.pgen.1002214.g003
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SOD1 mRNA in zebrafish embryos has been shown to cause
shortening and premature branching of axonal projections from
the motor neurons in the spinal cord [8] and is consistent with the
toxic gain of function observed in ALS [2,7,8]. Consistent with
these published results, we observed a motor phenotype consisting
of 33% of zebrafish with swimming deficits, 44% of zebrafish with
normal TEER and UAL of 81 mm when we overexpressed the
G93A mutant SOD1 in our zebrafish model (Figure 5Bi and
Figure 6A, 6Bv). Similarly, co-expression with mutant SOD1 of
WT TARDBP (motor phenotype consisting of 44% of zebrafish
with normal TEER and UAL of 80 mm) (Figure 5Biii) or FUS
(42% of zebrafish with normal TEER and UAL of 76 mm)
(Figure 5Bii) failed to rescue this motor deficit to any significant
extent, indicating that mutant SOD1 does not act upstream of
either of these two genes. These results are summarized in Table 1
rows 9, 19 and 35–37.
SOD1 acts independently of FUS/TARDBP
The foregoing results strongly suggest that SOD1 acts indepen-
dently of TARDBP and FUS in our models. If this is true, then the
motor phenotype yielded by either mutant SOD1 or TARDBP/
FUS alone should be less severe than the ‘‘additive’’ phenotype of
mutant SOD1 and TARDBP/FUS. Indeed, co-injection of both the
R521H mutant FUS and the G93A mutant SOD1 mRNAs (motor
phenotype consisting of 17% of zebrafish with normal TEER and
UAL of 68 mm) (Figure 5Biv and Figure 6A, 6Bvi) yielded an
exaggerated motor phenotype with a higher percentage of
embryos affected as well as an exacerbated axonal shortening
from motor neurons when compared to injection of mutant FUS
alone (42% of zebrafish with normal TEER and UAL of 78 mm)
(Figure 2A, 2Biv and Figure 5Ai) or mutant SOD1 (44% of
zebrafish with normal TEER and UAL of 81 mm) (Figure 5Bi and
Figure 6A, 6Bv) alone. Similarly, co-injection of mutant SOD1 and
of mutant TARDBP (motor phenotype consisting of 19% of
zebrafish with normal TEER and UAL of 68 mm) (Figure 5Bv) led
to a significantly exacerbated motor phenotype when compared to
mutant SOD1 alone (44% of zebrafish with normal TEER and
UAL of 81 mm) (Figure 5Bi and Figure 6A, 6Bv). The data in this
section are summarized in Table 1 rows 9, 19 and 38–39. These
results indicate that mutant SOD1 may yield a motor phenotype
which is additive with that generated by ALS-related FUS and
TARDBP mutations, suggesting that SOD1 may act independently
of TARDBP and FUS.
Discussion
Does a central pathogenic mechanism involving genetic
interactions of FUS and TARDBP lead to motor neuron
degeneration in ALS?
As summarized in the matrix of Figure 7A, here we show that
expression of WT FUS is able to rescue the motor phenotype
induced by KD of Fus (Figure 2) as well as the motor phenotype
caused by KD of zebrafish Tardbp (Figure 3 and Figure 4;
summarized in Figure 7A, green cell). On the other hand,
expression of WT TARDBP is unable to rescue the phenotype
caused by KD of Fus (Figure 3 and Figure 4; Figure 7A, red cell),
whereas it does rescue the motor phenotype induced by KD of
Tardbp. These results as well as in vitro reports of physical
interactions [35], [36] suggest that TARDBP and FUS share a
common genetic pathway, with FUS being downstream of
TARDBP. Alternatively, as certain studies have previously
Figure 4. FUS rescues the motor phenotype induced by Tardbp KD, but not vice-versa. A) Motor phenotype was assessed both by time
frames obtained from video recordings of the TEER as well as B) immunohistochemical labeling of the axonal projections to determine UAL in motor
neurons. The analysis shows that both expression of WT TARDBP and WT FUS can rescue the motor phenotype caused by KD of Tardbp (i) and Fus (ii)
respectively. Furthermore, WT FUS is able to rescue the motor phenotype induced by KD of Tardbp (iii), but WT TARDBP does not rescue the motor
phenotype caused by KD of Fus (iv). Similarly, WT SOD1 is unable to rescue Fus (v) and Tardbp (vi) KD phenotypes. Arrowheads represent length to the
first axonal branching (UAL). Scale bar: 40 mm.
doi:10.1371/journal.pgen.1002214.g004
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regulator, potentially capable of compensating for certain of the
functions of TARDBP [15]. This possibility is less likely since
overexpression of TAF15, a gene belonging to the class of TET
family of multifunctional DNA/RNA-binding proteins with high
functional and structural similarity to FUS was unable to rescue
the motor phenotype caused by Tardbp KD (Figure S2). The lack
of exacerbation of partial or more complete double knockdowns
also indicates a non-additive effect of TARDBP and FUS (Figure 5
and Figure S3). Although we were unable to generate an increased
phenotype upon double KD of Tardbp and Fus in this study, we
cannot exclude the possibility of phenotype exacerbation at
different doses of AMOs.
Expression of SOD1 was unable to rescue the phenotypes caused
by KD of Fus and/or Tardbp suggesting independent molecular
pathways (Figure 5 and Figure 6). Further, mutant SOD1 does not
appear to genetically converge with the pathogenic cascades
elicited by mutant TARDBP or FUS, since expression of mutant
SOD1 exacerbates the motor phenotype induced by mutant FUS
(as summarized in Figure 7A).
Although the pathological mechanisms through which ALS-
related TARDBP mutations cause motor neuron degeneration are
not understood, protein misfolding and phosphorylation, nuclear
to cytosolic shuttling and RNA imbalance are presumed to be
involved [11,15,16]. Our results suggest that certain ALS-related
FUS mutations, similarly to TARDBP [50], can cause motor
neuron deficits through both loss and toxic gain of function
mechanisms. As illustrated in Figure 7B, the molecular mecha-
nisms that cause motor neuron degeneration could be initiated
with a loss of function of FUS or TARDBP due to mislocalization
from the nucleus to the cytosol, whereas the toxic gain of function
could be the result of abnormal accumulation of aggregate-prone
proteins as reported for two of the FUS mutations described here,
R521H and R521C [14,54,55], as well as the mutations R495X,
R522G and P525L [59–61]. A similar toxic gain of function has
been described for the A315T, G348C and A382T TARDBP
mutations [48,50]. In fact, several of these recent studies and
others have shown that in neurons, expression of TDP-43 and/or
FUS in the cytosol causes aggregation of these proteins with
subsequent recruitment into stress granules, thus initiating
pathogenic events [59–63].
While this article was under review, a study in Drosophila
performed a functional characterization of several FUS mutations,
including the R521H and R521C mutations described here [37].
Figure 5. Double mutant and double KD interactions between SOD1 and TARDBP/FUS. A) Percentage for zebrafish with a normal TEER
(upward bars, averages of % of normal ZF embryos 6 SEM) and the length of the primary motor axons (UAL; downward bars, averages of UAL in mm
6 SEM) were measured. Motor phenotypes were observed upon overexpression of mutant R521H FUS alone (i), mutant G348C TARDBP alone (ii),
mutants R521H FUS with G348C TARDBP (iii), injection of Fus AMO alone (iv), Tardbp AMO alone (v; as in Figure 2Ai), and co-injection of Fus and
Tardbp AMOs (vi). B) Similarly, motor phenotypes were also observed upon expression of mutant G93A SOD1 alone (i) as well as co-expression with
WT FUS (ii), WT TARDBP (iii), mutant R521H FUS (iv), or mutant G348C TARDBP (v). Red bars indicate a significant (p,0.05) motor phenotype as
compared to expression of WT FUS alone (Figure 2Cix); black bars indicate an exacerbated phenotype compared to Bi (* p,0.05) compared to that
observed upon expression of mutant G93A SOD1 alone (i).
doi:10.1371/journal.pgen.1002214.g005
Figure 6. Mutant SOD1 exacerbates the motor phenotype caused by mutant FUS and mutant TARDBP. A) Motor phenotype was assessed
both by time frames obtained from video recordings of the TEER as well as B) immunohistochemical labeling of the axonal projections to determine
UAL in motor neurons. The analysis demonstrates that knock-down of both Tardbp and Fus (ii) does not lead to an exacerbated phenotype when
compared to phenotypes generated by KD of Tardbp (i) or Fus by AMOs. Similarly, overexpression of both mutant R521H FUS and G348C TARDBP (iv)
does not aggravate the phenotype observed by overexpression of mutant TARDBP (iii) or mutant FUS (Figure 2A, 2Biv). However, co-expression of
mutant SOD1 and mutant FUS did exacerbate the motor phenotype caused by mutant SOD1 alone (v). Arrowheads represent length to the first
axonal branching (UAL). Scale bar: 40 mm.
doi:10.1371/journal.pgen.1002214.g006
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an increased severity of the ‘‘rough-eye’’ phenotype, widespread
neurodegeneration and lethality as compared to WT FUS
overexpression [37]. The authors also suggested genetic interac-
tions between TARDBP and FUS since overexpression of both
mutants together caused exacerbation of this phenotype as
compared to expression of either mutant TARDBP or FUS.
However, overexpression of WT TARDBP and WT FUS together
caused similar increases in phenotype severity when compared to
overexpression of either WT genes alone [37]. Thus, this
exacerbation could be likely a result of excessive amounts of these
proteins, which have been found as likely to aggregate in a number
of models, including yeast [64–66]. On the other hand, we
describe here a genetic interaction due to rescue (as opposed to
exacerbation) by WT FUS of the motor phenotype upon Tardbp
KD, suggesting that FUS is downstream to TARDBP in this
pathway.
Consistent with a possible action downstream from TARDBP,
FUS is thought to have a more critical role in regulating neuronal
morphology and connectivity [15]. In cell lines, TDP-43 was
shown to form complexes with hnRNPs and a fraction of TDP-43
in these complexes does interact directly with FUS, with this in vitro
interaction being enhanced in cell lines from ALS patients
harboring TARDBP mutations [35]. Another study using cell lines
demonstrated that a common biochemical pathway exists where
FUS and TDP-43 interact by binding competitively HDAC6
mRNA, with TDP-43 being upstream in this pathway. Further,
since FUS antibodies have been shown to co-label TDP-43
positive protein aggregates observed in both SALS and FALS
cases, a similar pathogenic function for these mutant proteins has
been suggested [33]. Finally, ubiquitinated aggregates observed in
FALS cases with SOD1 mutations were not immunopositive
against TDP-43 or FUS antibodies [33,34], again consistent with
independent pathogenic mechanisms for SOD1 and TDP-43/
FUS.
Interactors of TARDBP are central in ALS genetics and
pathology
Interestingly, a number of in vivo studies have demonstrated that
TARDBP has a number of genetic interactors such as Ataxin-2
[46], progranulin (GRN) [48,67–69], valosin-containing protein
(VCP) [70,71] and histone deacetylase 6 (HDAC6) [36,38]. Most of
these interactors are mutated in other neurodegenerative disor-
ders, such as dementia and expanded polyglutamine repeat
disorders, whereas some may participate in generalized processes
such as autophagy. Further, recent genetic studies have shown that
mutations in Ataxin-2 and VCP are prevalent in ALS patients, with
intermediate polyglutamine expansions significantly associated
with ALS [46] and a study finding VCP mutations in 1–2% of
FALS patients [72]. These combined results suggest that TARDBP
plays a pivotal role in the pathogenic pathways leading to motor
neuron degeneration culminating in ALS. These results also
suggest that a multigenic pathway shared in a number of
neurodegenerative disorders may exist. Unraveling the molecular
and genetic components of this network of neurodegenerative
interactions could have major implications in our understanding of
the pathophysiology of these neurological disorders and could
accelerate the discovery of future treatments for these increasingly
prevalent diseases.
Materials and Methods
Ethics statement
Zebrafish were raised from a colony maintained according to
established procedures. All procedures described here were carried
out in compliance with the Canadian Council for Animal Care.
Embryonic RNA manipulation
Injections were performed in 1–4 cell stage blastulae. FUS WT
and mutants (R521H, R521C, S57D), TARDBP WT and mutant
(G348C), SOD1 WT and mutant (G93A) mRNAs were transcribed
from NotI-linearized pCS2+ using SP6 polymerase with the
mMESSAGE Machine Kit (Ambion). This was followed by a
phenol-chloroform purification and ethanol precipitation, and
diluted in nuclease-free water (Ambion). The mRNAs were diluted
in nuclease free water (Ambion) with 0.05% Fast Green vital dye
(Sigma) at a concentration of 60 ng/ml( FUS), 25 ng/ml( TARDBP)
and 100 ng/ml( SOD1) and were pulse-injected into early embryos
using a Picospritzer III (General Valve) pressure ejector. The
zebrafish TARDBP, FUS and SOD1 gene orthologues, Tardbp, Fus,
and Sod1 (NM_201476; NM_201083.2; and NM_131294.1
respectively) were identified using the Ensembl’s gene homology
prediction program (http://www.ensembl.org). AMOs were
designed to bind and inhibit specifically the ATG of the following
genes (and no other genomic sequence): Fus (GGCCATAAT-
CATTTGACGCCATGTT), Tardbp (GTACATCTCGGCCAT-
CTTTCCTCAG) and Sod1 (GCACACAAACGGCCTTGTT-
CACCAT) mRNA translation (Gene Tools) were designed
complimentary to the region of translational initiation of the Fus
CGAAGGCGACTGTACGTATAACACCTCAGAAATTGTT-
ATTCTGCATCATTTCTAAAAGGATTTTAAGCCCAAAC
[(ATG)GCGTCAAATGATTATGGCC]AAA, Tardbp (GGAAA-
CAGTTAGCACAGCTCGCGCATTCGGTGTAATC [(ATG)-
ACGGAGTGCTATATTCGTGTGG]), and Sod1 TCTTATCA-
AACACAGTCGGTTTCTTTCACTCTCTCACAACTTCTC-
AGTTTGCATAATCTACAGTCAGC [(ATG)GTGAACAAG-
GCCGTTTGTGTGC] mRNAs to inhibit protein translation.
These AMOs were designed to bind solely to the 1
st ATG of the
appropriate region of translational initiation for each gene and
were confirmed by BLAST searches to not recognize any other
sequences in the zebrafish genome (or any human transcripts). An
AMO having nucleotides that were mismatched represented as
lowercase to disrupt specificity were also designed for Fus (GG-
CgAaAATgATTTcACcCCATGTT). Dose-dependence curves of
AMO and mRNA toxicity were performed and AMOs were
injected at a concentration of 0.6 (Fus), 0.1 (Tardbp) and 0.5 (Sod1)
mM to minimize morpholino-induced developmental delay and
toxicity and to yield a consistent motor phenotype. Suboptimal
doses were established for Fus (0.3 mM) and Tardbp (0.05 mM).
Figure 7. Summary of multigenic interactions and a hypothetical ALS molecular network. A) A genetic matrix of the main interactions
described here with q representing phenotype due to overexpression of mutant mRNA and Q representing phenotype due to KD of the zebrafish
mRNA and ? for both phenotypes. ‘2’ stands for lack of rescue (i.e. motor phenotype), ‘+’ represents rescue. Note in green the rescue of the Tardbp
KD phenotype by WT FUS mRNA and in red the lack of rescue of the Fus KD phenotype by WT TARDBP mRNA. B) Cartoon summary of the proposed
ALS network with q representing motor phenotype due to overexpression of mutant mRNA and Q representing phenotype due to KD of the
zebrafish mRNA and ? for both phenotypes in which nuclear expression of TARDBP is upstream of FUS and both are independent of cytosolic
expression of SOD1. Loss of function (LOF) for FUS/TARDBP could be due to mislocalization from the nucleus, whereas gain of function (GOF) due to
abnormal levels of these aggregate-prone cytosolic proteins.
doi:10.1371/journal.pgen.1002214.g007
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Morphology and behavioral touch responses were assessed with
a stereomicroscope (Zeiss, Oberkochen, Germany) and only fish
with no obvious developmental deficits were selected to determine
the TEER. For escape swimming at 48 hpf, embryos were
touched lightly at the level of the tail or head with a pair of blunt
forceps. Fish that were unable to escape were touched several
times (3–4 times) in order to ascertain their failure to respond.
Thus, for each injection set, larvae were separated in four groups;
dead and developmentally deficient, fish with deficits in TEER
and fish displaying a normal TEER. The percentages for the two
last groups are described in Table 1 for each condition. Their
responses were also recorded using a Photron (San Diego, CA)
Fastcam PCI high-speed video camera at a rate of 125 frames/s.
Immunohistochemistry
For immunohistochemical analysis of axonal projections of
motor neurons, monoclonal antibodies anti-SV2 (Developmental
Studies Hybridoma) were used to assess the motor neuron
morphology at 48 and 72 hpf. Fluorescent images of fixed
embryos were taken using a Quorum Technologies spinning-disk
confocal microscope mounted on an upright Olympus BX61W1
fluorescence microscope equipped with an Hamamatsu ORCA-
ER camera. Image acquisition was performed with Volocity
software (PerkinElmer). As previously described [50], axonal
projections from primary and secondary motor neurons at a
defined location in the intersomitic segments were determined.
Analysis of Z-stacks by confocal microscopy was performed in
three to four axonal projections per animal. The axonal length to
the first branching (UAL) was determined by tracing the labeled
axon from the spinal cord to the point where it branches using
Image J. These values were averaged for each of the animal
analyzed (10–30 zebrafish per condition) for the various conditions
in our study.
In situ hybridization
Sense and antisense probes of 500 bp length against FUS
mRNA were designed. 24 hpf zebrafish embryos were processed
for in situ hybridization using fluorescent FastRed as previously
described [73], with minor modifications.
Western blotting
Zebrafish embryos were lysed in ice using cold SDS sample
buffer (63 mM Tris-HCl pH 6.8, 10% glycerol, 5% ß-mercapto-
ethanol, 3.5% sodium dodecyl sulfate) and were maintained on ice
and homogenized using a hand-held pestle. The lysates were
centrifuged for 15 minutes at 13000 rpm and separated into
soluble and insoluble fractions. SDS/PAGE Western blotting of
both fractions were carried out as previously described [9], using
monoclonal antibodies against myc (Invitrogen), actin (Clone C4;
ICN BIOMEDICALS, Inc.), a polyclonal antibodies against TDP-
43 (ProteinTech) and a polyclonal antibody (Bethyl Laboratories)
as well as a monoclonal antibody against FUS (BD Transduction
Laboratories).
Statistics
Statistical significance was determined by ANOVA and post hoc
analysis by Tukey’s multiple comparison test using Prism software
(Prism Software Ltd.) as well as a two-tailed distribution, two-
sample equal variance t-test using Sigma Plot software (Systat
Software Inc., San Jose, CA, USA). Significance was established at
p,0.05.
Supporting Information
Figure S1 FUS mutations are unable to rescue the phenotype
induced by KD of Fus. A) and B) Motor phenotype was assessed
both by time frames obtained from video recordings of the TEER
as well as immunohistochemical labeling of the axonal projections
of motor neurons to determine the UAL. The analysis demon-
strates that two ALS-related mutations, R521C (i) and S57D (ii),
unlike the R521H mutation, do not induce a significant motor
phenotype when compared to WT FUS mRNA expression.
Whereas R521C (iii) is unable to rescue the motor phenotype
induced by KD of Fus, WT (Figure 2) and the S57D mutation are
able to rescue the motor phenotype caused by Fus KD in zebrafish
embryos. All quantifications of the motor phenotype are given in
Figure 2 and Table 1. Scale bar: 40 mm.
(TIF)
Figure S2 TAF15,aFUS homologue is unable to rescue the
TEER induced by KD of Tardbp. A) Representative videos
showing the TEER when TAF15 mRNA was overexpressed (i),
upon Tardbp KD (ii), and co-injection of the Tardbp AMO and
TAF15 mRNA. B) Overexpression of TAF15 mRNA was unable
to rescue the TEER induced by Tardbp KD.
(TIF)
Figure S3 KD of both Tardbp and Fus in zebrafish does not
induce an exacerbated motor phenotype. A) Representative videos
showing the TEER of zebrafish larvae when subdoses of Fus AMO
(i), Tardbp AMO (ii) and co-injection of both these AMOs (iii). B)
An exacerbated TEER phenotype was not observed upon co-
injection of both these AMOs.
(TIF)
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